PACIRA BIOSCIENCES, INC. Deferred Income Tax Assets, Net
PACIRA BIOSCIENCES, INC. (PCRX) had Deferred Income Tax Assets, Net of $124.60 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-04
- 2026-06-30: Deferred Income Tax Assets, Net $124.60M.
- 2026-03-31: Deferred Income Tax Assets, Net $122.11M.
- 2025-12-31: Deferred Income Tax Assets, Net $123.85M.
- 2025-09-30: Deferred Income Tax Assets, Net $120.19M.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $124.60M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $122.11M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $123.85M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $120.19M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $128.27M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $129.01M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $130.38M 10-K · filed 2026-02-26 |
| 2024-09-30 | $134.02M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $135.14M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $141.06M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $144.49M 10-K · filed 2025-02-27 |
| 2023-09-30 | $151.66M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $156.14M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $167.57M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $160.31M 10-K · filed 2024-02-29 |
| 2022-09-30 | $155.53M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $167.15M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $169.28M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $153.36M 10-K · filed 2023-02-28 |
| 2021-09-30 | $93.27M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $98.60M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $104.47M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $106.16M 10-K · filed 2022-02-28 |
| 2020-09-30 | $104.12M 10-Q · filed 2020-10-30 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |